A Phase I/Ib, Study of KAZ954 as a Single Agent and in Combination With Spartalizumab, NZV930 and NIR178 in Patients With Advanced Solid Tumors

Phase 1

Completed

• Conditions: Solid Tumors

• Registration Number: JPRN-jRCT2080225114
• Lead Sponsor: ovartis Pharma. K.K.

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2020-03-05
• Last Update Posted: 2024-01-22

Recruitment & Eligibility

• Status: completed
• Sex: All
• Target Recruitment: 145

Inclusion Criteria

Patients with metastatic and/or advanced malignancies not amenable to curative treatment by surgery.
- Must have a site of disease amenable to biopsy and be a candidate for tumor biopsy according to the treating institution's guidelines. Patient must be willing to undergo a new tumor biopsy at screening and during the study.
- ECOG Performance Status of <2.

Exclusion Criteria

- Presence of symptomatic central nervous system (CNS) metastases, or CNS metastases that require concurrent treatment - including surgery, radiation and/or corticosteroids.
- History of severe hypersensitivity reaction to any ingredient of study drug(s) and other mAbs and/or their excipients.
- Impaired cardiac function HIV Known history of tuberculosis Systemic chronic steroid therapy
- Other protocol-defined inclusion/exclusion criteria may apply.

Study & Design

• Study Type: Interventional
• Study Design: Not specified